Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras

Journal of Gastroenterology

Volumn 51, Issue 5, 2016, Pages 447-457

  Kawaguchi, Yasuo ^a   Hinoi, Takao ^a   Saito, Yasufumi ^a   Adachi, Tomohiro ^a   Miguchi, Masashi ^a   Niitsu, Hiroaki ^a   Sasada, Tatsunari ^a   Shimomura, Manabu ^a   Egi, Hiroyuki ^a   Oka, Shiro ^b   Tanaka, Shinji ^b   Chayama, Kazuaki ^a   Sentani, Kazuhiro ^a   Oue, Naohide ^a   Yasui, Wataru ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Glut1; Kras

Indexed keywords

APC PROTEIN; CRE RECOMBINASE; GLUCOSE TRANSPORTER 1; K RAS PROTEIN; INTEGRASE; KRAS2 PROTEIN, MOUSE; PROTEIN P21; SLC2A1 PROTEIN, MOUSE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCENDING COLON; CARCINOGENESIS; COLON TUMOR; COLORECTAL CANCER; EXPERIMENTAL MODEL; GENE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STAINING; TRANSGENE; ANIMAL; COLON; COLORECTAL TUMOR; DISEASE MODEL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; MUTATION; PATHOLOGY; TRANSGENIC MOUSE; UPREGULATION; VALIDATION STUDY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CARCINOGENESIS; COLON; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; INTEGRASES; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSATELLITE INSTABILITY; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS P21(RAS); UP-REGULATION;

EID: 84941352152     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1121-9     Document Type: Article

References (45)

1. Lievre A, Bachet JB, Boige V, et al. Kras mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–9.
2. De Roock W, Piessevaux H, De Schutter J, et al. Kras wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–15.
3. Heinemann V, von Weikersthal LF, Decker T, et al. Folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (fire-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.
4. Schwartzberg LS, Rivera F, Karthaus M, et al. Peak: a randomized, multicenter phase ii study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mfolfox6) or bevacizumab plus mfolfox6 in patients with previously untreated, unresectable, wild-type kras exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32:2240–7.
5. Barbacid M. Ras genes. Annu Rev Biochem. 1987;56:779–827.
6. Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of kras, braf, and nras mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50:307–12.
7. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. Ras oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74.
8. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic k-ras and n-ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40:600–8.
9. Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase iii study of metastatic colorectal cancer. Clin Cancer Res. 2013;19:1902–12.
10. Schirripa M, Cremolini C, Loupakis F, et al. Role of nras mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136:83–90.
11. Sorich MJ, Wiese MD, Rowland A, et al. Extended ras mutations and anti-egfr monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:13–21.
12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.
13. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059–72.
14. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546–58.
15. Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148:88–99.
16. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(2073–87):e3.
17. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–52.
18. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the apc gene. Science. 1992;256:668–70.
19. Taketo MM. Mouse models of gastrointestinal tumors. Cancer Sci. 2006;97:355–61.
20. Young M, Ordonez L, Clarke AR. What are the best routes to effectively model human colorectal cancer? Mol Oncol. 2013;7:178–89.
21. Zeineldin M, Neufeld KL. Understanding phenotypic variation in rodent models with germline apc mutations. Cancer Res. 2013;73:2389–99.
22. Hinoi T, Gesina G, Akyol A, et al. Cdx2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology. 2005;128:946–61.
23. Hinoi T, Loda M, Fearon ER. Silencing of cdx2 expression in colon cancer via a dominant repression pathway. J Biol Chem. 2003;278:44608–16.
24. Hinoi T, Lucas PC, Kuick R, et al. Cdx2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology. 2002;123:1565–77.
25. Takakura Y, Hinoi T, Oue N, et al. Cdx2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium. Cancer Res. 2010;70:6767–78.
26. Hinoi T, Akyol A, Theisen BK, et al. Mouse model of colonic adenoma-carcinoma progression based on somatic apc inactivation. Cancer Res. 2007;67:9721–30.
27. Akyol A, Hinoi T, Feng Y, et al. Generating somatic mosaicism with a cre recombinase-microsatellite sequence transgene. Nat Methods. 2008;5:231–3.
28. Sasada T, Hinoi T, Saito Y, et al. Chlorinated water modulates the development of colorectal tumors with chromosomal instability and gut microbiota in apc-deficient mice. PLoS One. 2015;10:e0132435.
29. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic k-ras(g12d) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5:375–87.
30. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of kras pathway mutations in tumor cells. Science. 2009;325:1555–9.
31. Shibata H, Toyama K, Shioya H, et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science. 1997;278:120–3.
32. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic k-ras. Genes Dev. 2001;15:3243–8.
33. Prante O, Maschauer S, Fremont V, et al. Regulation of uptake of 18f-fdg by a follicular human thyroid cancer cell line with mutation-activated k-ras. J Nucl Med. 2009;50:1364–70.
34. Iwamoto M, Kawada K, Nakamoto Y, et al. Regulation of 18f-fdg accumulation in colorectal cancer cells with mutated kras. J Nucl Med. 2014;55:2038–44.
35. Sansom OJ, Meniel V, Wilkins JA, et al. Loss of apc allows phenotypic manifestation of the transforming properties of an endogenous k-ras oncogene in vivo. Proc Natl Acad Sci USA. 2006;103:14122–7.
36. Hung KE, Maricevich MA, Richard LG, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA. 2010;107:1565–70.
37. Byun AJ, Hung KE, Fleet JC, et al. Colon-specific tumorigenesis in mice driven by cre-mediated inactivation of apc and activation of mutant kras. Cancer Lett. 2014;347:191–5.
38. Luo F, Brooks DG, Ye H, et al. Conditional expression of mutated k-ras accelerates intestinal tumorigenesis in msh2-deficient mice. Oncogene. 2007;26:4415–27.
39. Janssen KP, Alberici P, Fsihi H, et al. Apc and oncogenic kras are synergistic in enhancing wnt signaling in intestinal tumor formation and progression. Gastroenterology. 2006;131:1096–109.
40. Luo F, Brooks DG, Ye H, et al. Mutated k-ras(asp12) promotes tumourigenesis in apc(min) mice more in the large than the small intestines, with synergistic effects between k-ras and wnt pathways. Int J Exp Pathol. 2009;90:558–74.
41. Biswas S, Trobridge P, Romero-Gallo J, et al. Mutational inactivation of tgfbr2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes Chromosom Cancer. 2008;47:95–106.
42. Ionov Y, Yamamoto H, Krajewski S, et al. Mutational inactivation of the proapoptotic gene bax confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA. 2000;97:10872–7.
43. Hempen PM, Zhang L, Bansal RK, et al. Evidence of selection for clones having genetic inactivation of the activin a type ii receptor (acvr2) gene in gastrointestinal cancers. Cancer Res. 2003;63:994–9.
44. Woerner SM, Tosti E, Yuan YP, et al. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors. Mol Carcinog. 2014. doi:10.1002/mc.22213.
45. Kucherlapati MH, Lee K, Nguyen AA, et al. An msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology. 2010;138(993–1002):e1.